7th International Symposium on Photodynamic Therapy and Photodiagnosis in Clinical Practice
Professor David Phillips, a co-founder of PhotoBiotics Ltd, gave a very well-received plenary lecture entitled "Towards Targeted Photodynamic Therapy" at this prestigious bi-annual conference.
He presented the company's latest results on the selective in vivo destruction of tumours, using PhotoBiotics' novel targeted approach of multiple photosensitisers attached to monoclonal antibody fragments (sc-Fvs).
The symposium highlighted several research groups' attempts specifically to target photosensitisers to tumours (e.g., using whole monoclonal antibodies, nano-particles, liposomes, and folic acid).
PhotoBiotics' demonstration of the superior photosensitiser loading and targeting properties of its much smaller sc-Fvs, was thought by many at the symposium to represent an important milestone in the development of photodynamic therapy that had the potential to significantly improve its clinical outcomes.
For more information please contact:
Dr Lionel R Milgrom, PhotoBiotics Ltd Press Office,
Tel: +44 (0)208 450 8760
Mob: +44 (0)7970 852156
Email: media@photobiotics.com
News Items
- The Sunday Times reports on PDT (24 November 2010)
- New Agent Boosts Prospects for Photodynamic Therapy (18 August 2010)
- 'The Times' reports on laser surgery (3 April 2010)
- US patent granted to PhotoBiotics (1 April 2010)
- Prince of Wales highlights PDT in Cancer therapy (2 February 2010)
- Conference Success in Brixen, Italy (12 December 2008)
- PhotoBiotics: Imperial spin-out looks for partners (6 February 2008)
- Imperial spin-out gains investment, and investors (31 January 2008)
- Light-Activated Cancer Therapy Could Have Glowing Prospects (19 December 2007)
- Light shines on antibodies (16 November 2007)
- New targeted approach to light-activated cancer drugs (08 November 2007)
- Cancer-seeking antibodies guide light-sensitive drugs (03 August 2007)